October 2, 2025

Supplementary Figure S1 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Key Points

Higher adjusted hazard ratios indicate differing overall survival between brcaalt and no brcaalt groups.
Time to castrate-resistance is notably affected by brcaalt status during treatment with arpi.
Patients with brcaalt show distinct treatment outcomes compared to those without alterations in prostate cancer therapies.
ARPI and taxane treatments demonstrate varying effectiveness based on brcaalt and overall survival metrics.

Abstract

Outcomes on ARPI or taxane by BRCAalt status. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for BRCAalt vs. no BRCAalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

اسأل الذكاء الاصطناعي

Bookmark